Skip to content
TrialScanner

NCT07708727

Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment

Phase 2/Phase 3RecruitingGILDLead

Registry record

Lead sponsor
Gilead Sciences
Conditions
HIV-1-infection
Primary completion
Oct 2030Sponsor estimate
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Sponsor estimate: the sponsor registered this date in advance and can move it. A primary completion date is when the last participant is measured, not when results are announced.

Open NCT07708727 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT07708727: Study of an Injectable... | TrialScanner